+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ionis Pharmaceuticals Inc (IONS) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 56 Pages
  • May 2022
  • GlobalData
  • ID: 1290964
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Ionis Pharmaceuticals Inc (IONS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights


Ionis Pharmaceuticals Inc (Ionis), formerly ISIS Pharmaceuticals, Inc., focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.

Ionis Pharmaceuticals Inc Key Recent Developments

  • May 04, 2022: Ionis reports first quarter financial results and recent business achievements
  • May 02, 2022: Ionis to host 2022 virtual Annual Meeting of Stockholders
  • Mar 21, 2022: Ionis to present at upcoming investor conferences
  • Mar 07, 2022: Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
  • Feb 24, 2022: Ionis reports fourth quarter and full year 2021 financial results and recent business achievements

Key benefits of buying this profile include:

  • You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Ionis Pharmaceuticals Inc - Key Facts
  • Ionis Pharmaceuticals Inc - Key Employees
  • Ionis Pharmaceuticals Inc - Key Employee Biographies
  • Ionis Pharmaceuticals Inc - Major Products and Services
  • Ionis Pharmaceuticals Inc - History
  • Ionis Pharmaceuticals Inc - Company Statement
  • Ionis Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Affiliate

Section 2 - Company Analysis
  • Company Overview
  • Ionis Pharmaceuticals Inc - Business Description
  • Product Category: Commercial Revenue
  • Overview
  • Performance
  • Product Category: R&D Revenue under Collaborative Agreements
  • Performance
  • R&D Overview
  • Ionis Pharmaceuticals Inc - Corporate Strategy
  • Ionis Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Ionis Pharmaceuticals Inc - Strengths
  • Ionis Pharmaceuticals Inc - Weaknesses
  • Ionis Pharmaceuticals Inc - Opportunities
  • Ionis Pharmaceuticals Inc - Threats
  • Ionis Pharmaceuticals Inc - Key Competitors

Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Ionis Pharmaceuticals Inc, Recent Deals Summary

Section 5 - Company’s Recent Developments
  • May 04, 2022: Ionis reports first quarter financial results and recent business achievements
  • May 02, 2022: Ionis to host 2022 virtual Annual Meeting of Stockholders
  • Mar 21, 2022: Ionis to present at upcoming investor conferences
  • Mar 07, 2022: Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
  • Feb 24, 2022: Ionis reports fourth quarter and full year 2021 financial results and recent business achievements
  • Jan 19, 2022: Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy
  • Jan 05, 2022: Biogen to obtain licence for Ionis’ investigational SMA therapy
  • Jan 05, 2022: Ionis to present at 40th Annual JP Morgan Healthcare conference
  • Jan 03, 2022: Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
  • Dec 08, 2021: AstraZeneca and Ionis partner to develop antisense therapy eplontersen

Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact Us
  • Disclaimer

List of Tables
  • Ionis Pharmaceuticals Inc, Key Facts
  • Ionis Pharmaceuticals Inc, Key Employees
  • Ionis Pharmaceuticals Inc, Key Employee Biographies
  • Ionis Pharmaceuticals Inc, Major Products and Services
  • Ionis Pharmaceuticals Inc, History
  • Ionis Pharmaceuticals Inc, Other Locations
  • Ionis Pharmaceuticals Inc, Subsidiaries
  • Ionis Pharmaceuticals Inc, Affiliate
  • Ionis Pharmaceuticals Inc, Key Competitors
  • Ionis Pharmaceuticals Inc, Ratios based on current share price
  • Ionis Pharmaceuticals Inc, Annual Ratios
  • Ionis Pharmaceuticals Inc, Interim Ratios
  • Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Ionis Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Ionis Pharmaceuticals Inc, Performance Chart (2017 - 2021)
  • Ionis Pharmaceuticals Inc, Ratio Charts
  • Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • XOMA Corp
  • Stealth BioTherapeutics Corp
  • Rezolute Inc
  • OSE Immunotherapeutics SA
  • NeuroBo Pharmaceuticals Inc
  • Intercept Pharmaceuticals Inc
  • Enzo Biochem Inc
  • BridgeBio Pharma Inc
  • Arrowhead Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc